Literature DB >> 18714398

Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas.

Lukasz-Filip Grochola1, Thomas Greither, Helge W Taubert, Peter Möller, Uwe Knippschild, Andrej Udelnow, Doris Henne-Bruns, Peter Würl.   

Abstract

Telomerase is thought to play an essential role in tumorigenesis and progression. Its activity is directly correlated with the expression of its catalytic subunit, human telomerase reverse transcriptase (hTERT). A correlation of transcript expression with a poor prognosis has been detected in different human malignancies. However, data on hTERT in pancreatic ductal adenocarcinoma (PDAC) are purely descriptive so far. Therefore, we evaluated the impact of hTERT expression on patients' prognosis. Human telomerase reverse transcriptase mRNA isolates from 56 human microdissected PDAC tissues were analyzed by quantitative reverse transcription-polymerase chain reaction and multivariate Cox regression hazard test. Elevated hTERT transcript levels were measured in 23 of 56 PDAC tissues, 33 patients showed no detectable transcripts. Unexpectedly, a low expression of hTERT mRNA levels was associated with a worse prognosis for overall survival (relative risk = 5.33; P = .013) when compared to high levels, whereas undetectable expression showed an intermediate risk of tumor-related death. These data challenge previous findings outlining hTERT's negative impact on overall survival. The risk pattern obtained in PDAC suggests a more complex regulation of hTERT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18714398      PMCID: PMC2517642          DOI: 10.1593/neo.08578

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  30 in total

1.  The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity.

Authors:  L M Colgin; C Wilkinson; A Englezou; A Kilian; M O Robinson; R R Reddel
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

2.  Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity.

Authors:  A L Ducrest; M Amacker; Y D Mathieu; A P Cuthbert; D A Trott; R F Newbold; M Nabholz; J Lingner
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

3.  The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres.

Authors:  Ramiro E Verdun; Jan Karlseder
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

Review 4.  The significance of human telomerase reverse transcriptase (hTERT) in cancer.

Authors:  K L Kirkpatrick; K Mokbel
Journal:  Eur J Surg Oncol       Date:  2001-12       Impact factor: 4.424

5.  An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity.

Authors:  X Yi; D M White; D L Aisner; J A Baur; W E Wright; J W Shay
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

6.  Bcl-2 modulates telomerase activity.

Authors:  M Mandal; R Kumar
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

7.  Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas.

Authors:  J Nakayama; H Tahara; E Tahara; M Saito; K Ito; H Nakamura; T Nakanishi; E Tahara; T Ide; F Ishikawa
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

8.  Serum tumor markers and molecular biological diagnosis in pancreatic cancer.

Authors:  Norio Sawabu; Hiroyuki Watanabe; Yasushi Yamaguchi; Koushirou Ohtsubo; Yoshiharu Motoo
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

9.  Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.

Authors:  Hisashi Hisatomi; Kazuma Ohyashiki; Junko H Ohyashiki; Kumi Nagao; Taichi Kanamaru; Hiroyuki Hirata; Nozomu Hibi; Yutaka Tsukada
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

10.  Myc activates telomerase.

Authors:  J Wang; L Y Xie; S Allan; D Beach; G J Hannon
Journal:  Genes Dev       Date:  1998-06-15       Impact factor: 11.361

View more
  8 in total

1.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

2.  Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer.

Authors:  Yi Kang; Jiancheng Zhang; Peichun Sun; Jia Shang
Journal:  Int J Clin Oncol       Date:  2012-04-12       Impact factor: 3.402

3.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

4.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 5.  Expression of telomerase & its significance in the diagnosis of pancreatic cancer.

Authors:  Anutebeh Verdo Zisuh; Tian-Quan Han; Shen-Dao Zhan
Journal:  Indian J Med Res       Date:  2012       Impact factor: 2.375

6.  Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells.

Authors:  Dorrah Deeb; Xiaohua Gao; Yongbo Liu; Kirit Pindolia; Subhash C Gautam
Journal:  Oncol Rep       Date:  2015-05-19       Impact factor: 3.906

7.  Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways.

Authors:  Dorrah Deeb; Chris Brigolin; Xiaohua Gao; Yongbo Liu; Kirit R Pindolia; Subhash C Gautam
Journal:  J Carcinog Mutagen       Date:  2014-05-31

8.  Theragnostic chromosomal rearrangements in treatment-naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound.

Authors:  Stephen J Murphy; Michael J Levy; James B Smadbeck; Giannoula Karagouga; Alexa F McCune; Faye R Harris; Julia B Udell; Sarah H Johnson; Sarah E Kerr; John C Cheville; Benjamin R Kipp; George Vasmatzis; Ferga C Gleeson
Journal:  J Cell Mol Med       Date:  2021-03-11       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.